Table 1.
Clinicopathological parameters of WHOest, WHOnew, and ICCnew
| MP-WHOest n = 551∗ |
MD-WHOest n = 654∗ |
WHOnew n = 356∗ |
q value† MD-WHOest vs WHOnew | ICCnew n = 241∗ |
q value† MD-WHOest vs ICCnew | |
|---|---|---|---|---|---|---|
| Age, y | 74.3 ± 8.6; 76.3 (37.8-93.3) | 74.3 ± 9.1; 75.6 (19.9-92.7) | 74.2 ± 9.3; 75.9 (30.8-91.9) | 0.9 | 75.3 ± 8.1; 76.8 (43.8-91.9) | 0.12 |
| Sex | 0.2 | 0.3 | ||||
| Female | 171/551 (31%) | 171/654 (26%) | 107/356 (30%) | 71/241 (29%) | ||
| Male | 380/551 (69%) | 483/654 (74%) | 249/356 (70%) | 170/241 (71%) | ||
| Clinical status | ||||||
| First diagnosis | 551/551 (100%) | 654/654 (100%) | 356/356 (100%) | 241/241 (100%) | ||
| Absolute monocyte count (PB), per nL | 9371.7 ± 12 137.4; 5667.0 (1240.0-95 680.0) | 1971.4 ± 1061.1; 1622.5 (1000.0-8160.0) | 709.3 ± 140.0; 694.5 (500.0-998.4) | <0.001 | 713.9 ± 138.5; 704.0 (500.0-998.4) | <0.001 |
| % Monocytes (PB) | 26.7 ± 13.2; 24.0 (10.0-79.0) | 28.1 ± 11.2; 26.0 (10.0-70.0) | 16.2 ± 6.4; 14.0 (10.0-46.0) | <0.001 | 16.6 ± 6.4; 15.0 (10.0-43.0) | <0.001 |
| White blood count, per nL | 35 358.9 ± 33 350.0; 24 800.0 (13 000.0-370 580.0) | 7171.5 ± 2845.8; 6850.0 (750.0-12 990.0) | 4856.4 ± 1687.5; 4700.0 (1500.0-9960.0) | <0.001 | 4786.7 ± 1704.7; 4600.0 (1500.0-9960.0) | <0.001 |
| Hemoglobin, g/dL | 10.9 ± 2.3; 10.9 (4.0-18.7) | 11.3 ± 2.3; 11.2 (4.3-19.6) | 10.7 ± 2.2; 10.6 (4.3-19.6) | <0.001 | 10.5 ± 2.0; 10.3 (4.3-16.3) | <0.001 |
| HB <9 g/dL (transfusion dependency) | 96/546 (18%) | 95/649 (15%) | 54/349 (15%) | 0.7 | 43/238 (18%) | 0.2 |
| Platelets (per nL) | 168 240.9 ± 196 848.4; 114 500.0 (4000.0-1 809 000.0) | 138 521.6 ± 123 464.7; 108 000.0 (4000.0-1 385 000.0) | 197 412.6 ± 151 556.8; 148 000.0 (4000.0-988 000.0) | <0.001 | 196 071.4 ± 161 420.0; 138 000.0 (4000.0-988 000.0) | <0.001 |
| Absolute neutrophil count (PB, per nL) | 17 228.5 ± 16 322.8; 12 266.5 (1400.0-138 250.0) | 3316.8 ± 2053.3; 2866.5 (180.0-9144.0) | 2509.7 ± 1370.8; 2355.0 (124.8-7669.2) | <0.001 | 2463.8 ± 1412.3; 2172.5 (136.8-7669.2) | <0.001 |
| % Neutrophils (PB) | 52.5 ± 14.8; 54.0 (8.0-82.0) | 42.4 ± 15.6; 43.0 (5.0-79.0) | 48.9 ± 15.2; 50.0 (6.0-80.0) | <0.001 | 48.5 ± 15.4; 49.0 (6.0-80.0) | <0.001 |
| Cytopenic lineages | <0.001 | <0.001 | ||||
| 0 | 31/551 (5.6%) | 28/654 (4.3%) | 13/352 (3.7%) | 0/241 (0%) | ||
| 1 | 257/551 (47%) | 299/654 (46%) | 157/352 (45%) | 112/241 (46%) | ||
| 2 | 262/551 (48%) | 284/654 (43%) | 120/352 (34%) | 81/241 (34%) | ||
| 3 | 1/551 (0.2%) | 43/654 (6.6%) | 62/352 (18%) | 48/241 (20%) | ||
| % blasts (PB) | 1.2 ± 2.2; 0.0 (0.0-12.0) | 0.4 ± 1.4; 0.0 (0.0-14.0) | 0.2 ± 1.1; 0.0 (0.0-11.0) | <0.001 | 0.3 ± 1.2; 0.0 (0.0-11.0) | 0.002 |
| % blasts (BM) | 7.0 ± 5.0; 6.0 (0.0-19.5) | 6.3 ± 4.1; 5.5 (0.0-19.5) | 4.0 ± 3.5; 3.0 (0.0-18.0) | <0.001 | 4.4 ± 3.7; 3.5 (0.0-18.0) | <0.001 |
| Blasts in PB and BM | <0.001 | <0.001 | ||||
| <2% PB blasts and <5% BM blasts | 203/551 (37%) | 258/654 (39%) | 256/356 (72%) | 164/241 (68%) | ||
| ≥2% and <10% PB blasts or ≥5% and <10% BM blasts | 202/551 (37%) | 275/654 (42%) | 72/356 (20%) | 57/241 (24%) | ||
| ≥10% and <20% PB blasts or ≥10% and <20% BM blasts | 146/551 (26%) | 121/654 (19%) | 28/356 (7.9%) | 20/241 (8.3%) | ||
| Percentage of monocytes (BM), % | 15.9 ± 11.6; 13.0 (0.0-77.5) | 13.9 ± 10.3; 12.0 (0.0-77.0) | 4.7 ± 4.5; 3.5 (0.0-38.5) | <0.001 | 4.2 ± 4.1; 3.0 (0.0-31.0) | <0.001 |
| Ringsideroblasts (BM, in %) | 3.7 ± 12.1; 0.0 (0.0-89.0) | 7.7 ± 19.8; 0.0 (0.0-96.0) | 20.6 ± 30.2; 0.0 (0.0-97.0) | <0.001 | 23.6 ± 31.8; 1.0 (0.0-97.0) | <0.001 |
| Esterase positivity (BM, in %) | 19.7 ± 14.7; 20.0 (0.0-80.0) | 16.2 ± 13.3; 15.0 (0.0-70.0) | 6.6 ± 9.9; 0.0 (0.0-60.0) | <0.001 | 7.1 ± 10.5; 0.0 (0.0-60.0) | <0.001 |
| Cellularity (BM) | <0.001 | <0.001 | ||||
| Hypercellular | 474/551 (86%) | 506/654 (77%) | 250/356 (70%) | 241/241 (100%) | ||
| Hypocellular | 21/551 (3.8%) | 67/654 (10%) | 24/356 (6.7%) | 0/241 (0%) | ||
| Normal | 56/551 (10%) | 81/654 (12%) | 82/356 (23%) | 0/241 (0%) | ||
| Dysplastic lineages (BM) | <0.001 | 0.004 | ||||
| 0 | 112/551 (20%) | 81/654 (12%) | 0/356 (0%) | 12/241 (5.0%) | ||
| 1 | 167/551 (30%) | 141/654 (22%) | 93/356 (26%) | 45/241 (19%) | ||
| 2 | 161/551 (29%) | 230/654 (35%) | 132/356 (37%) | 88/241 (37%) | ||
| 3 | 111/551 (20%) | 202/654 (31%) | 131/356 (37%) | 96/241 (40%) | ||
| Karyotype risk score | <0.001 | <0.001 | ||||
| 0 | 431/551 (78%) | 560/654 (86%) | 258/356 (72%) | 177/241 (73%) | ||
| 1 | 54/551 (9.8%) | 45/654 (6.9%) | 47/356 (13%) | 28/241 (12%) | ||
| 2 | 66/551 (12%) | 49/654 (7.5%) | 51/356 (14%) | 36/241 (15%) | ||
| Molecular risk score | 0.077 | 0.11 | ||||
| 0 | 84/390 (22%) | 262/531 (49%) | 143/246 (58%) | 91/158 (58%) | ||
| 1 | 105/390 (27%) | 112/531 (21%) | 44/246 (18%) | 26/158 (16%) | ||
| 2 | 81/390 (21%) | 68/531 (13%) | 32/246 (13%) | 24/158 (15%) | ||
| 3 | 120/390 (31%) | 89/531 (17%) | 27/246 (11%) | 17/158 (11%) | ||
| CPSS-Mol (complete observations) | <0.001 | 0.029 | ||||
| Low | 0/429 (0%) | 113/543 (21%) | 95/256 (37%) | 54/168 (32%) | ||
| Intermediate 1 | 37/429 (8.6%) | 172/543 (32%) | 70/256 (27%) | 46/168 (27%) | ||
| Intermediate 2 | 180/429 (42%) | 191/543 (35%) | 68/256 (27%) | 53/168 (32%) | ||
| High | 212/429 (49%) | 67/543 (12%) | 23/256 (9.0%) | 15/168 (8.9%) | ||
| CPSS (complete observations) | 0.021 | 0.012 | ||||
| Low | 0/548 (0%) | 401/650 (62%) | 198/349 (57%) | 133/238 (56%) | ||
| Intermediate 1 | 282/548 (51%) | 173/650 (27%) | 90/349 (26%) | 61/238 (26%) | ||
| Intermediate 2 | 227/548 (41%) | 69/650 (11%) | 60/349 (17%) | 44/238 (18%) | ||
| High | 39/548 (7.1%) | 7/650 (1.1%) | 1/349 (0.3%) | 0/238 (0%) | ||
| Mean IPSS-M | ||||||
| Very low | 52/356 (15%) | 22/241 (9.1%) | ||||
| Low | 165/356 (46%) | 113/241 (47%) | ||||
| Moderate low | 51/356 (14%) | 42/241 (17%) | ||||
| Moderate high | 32/356 (9.0%) | 21/241 (8.7%) | ||||
| High | 35/356 (9.8%) | 25/241 (10%) | ||||
| Very high | 21/356 (5.9%) | 18/241 (7.5%) | ||||
| IPSS-R | ||||||
| Very low | 77/348 (22%) | 45/237 (19%) | ||||
| Low | 162/348 (47%) | 109/237 (46%) | ||||
| Intermediate | 68/348 (20%) | 53/237 (22%) | ||||
| High | 33/348 (9.5%) | 25/237 (11%) | ||||
| Very high | 8/348 (2.3%) | 5/237 (2.1%) |
BM, bone marrow; HB, hemoglobin; PB, peripheral blood; SD, standard deviation,
∗
n / N (%); mean ± SD; median (range).
†
Pearson χ2 test; Wilcoxon rank sum test; and Fisher exact test after false discovery rate correction for multiple testing.